Decrease the activity of the IGF-1 axis could be a desirable target for reducing cancer risk [69], but it is also well known that the activation of the IGF-1/AKT/mTOR (insulin-like growth factor-1/protein kinase B/mammalian target of rapamycin) pathway is one of the keys for muscular growth. The gene discussed is AKT1; the disease is cancer.